Empagliflozin Particularly Effective in ' Vulnerable ' Diabetes Subgroup Empagliflozin Particularly Effective in ' Vulnerable ' Diabetes Subgroup
Empagliflozin reduced cardiac death with no signal of increased risk of amputation in patients with type 2 diabetes and PAD in EMPA-REG, with an NNT that was lower than for the trial population as a whole.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Cardiology News Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance